Probiodrug continues to expect data from the Phase IIa study of lead product candidate PQ912 around mid-2016. In the meantime, Eli Lilly is expected to announce initial data from the Phase I trial of its antibody-targeting pGlu-Abeta in Q415. This will have read-across to PBD-C06, Probiodrug’s preclinical pGlu-Abeta antibody. Current cash should provide sufficient funding until the PQ912 data readout, when Probiodrug may seek to partner PQ912. We value Probiodrug at €217.5m or &eur
23 Sep 2015
On track for PQ912 data mid-2016
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
On track for PQ912 data mid-2016
Probiodrug continues to expect data from the Phase IIa study of lead product candidate PQ912 around mid-2016. In the meantime, Eli Lilly is expected to announce initial data from the Phase I trial of its antibody-targeting pGlu-Abeta in Q415. This will have read-across to PBD-C06, Probiodrug’s preclinical pGlu-Abeta antibody. Current cash should provide sufficient funding until the PQ912 data readout, when Probiodrug may seek to partner PQ912. We value Probiodrug at €217.5m or &eur